Abstract:Schizophrenia is highly heritable and aggregating in families, but genetics alone does not exclusively explain the pathogenesis. Many risk factors, including childhood trauma, viral infections, migration, and the use of cannabis, are associated with schizophrenia. Adolescence seems to be the critical period where symptoms of the disease manifest. This work focuses on studying an epigenetic regulatory mechanism (the role of DNA methylation) and its interaction with mRNA expression during development, with a particular emphasis on adolescence. The presumptions regarding the role of aberrant neurodevelopment in schizophrenia were tested in the Methyl-Azoxy-Methanol (MAM) animal model. MAM treatment induces neurodevelopmental disruptions and behavioral deficits in off-springs of the treated animals reminiscent of those observed in schizophrenia and is thus considered a promising model for studying this pathology. On a gestational day-17, adult pregnant rats were treated with the antimitotic agent MAM. Experimental animals were divided into groups and subgroups according to substance treatment (MAM and vehicle agent [Sham]) and age of analysis (pre-adolescent and post-adolescent). Methylation and mRNA expression analysis of four candidate genes, which are often implicated in schizophrenia, with special emphasis on the Dopamine hypothesis i.e., Dopamine receptor D 2 ( Drd2 ), and the "co-factors" Disrupted in schizophrenia 1 ( DISC1 ), Synaptophysin ( Syp) , and Dystrobrevin-binding protein 1 ( Dtnbp1 ), was performed in the Gyrus cingulum (CING) and prefrontal cortex (PFC). Data were analyzed to observe the effect of substance treatment between groups and the impact of adolescence within-group. We found reduced pre-adolescent expression levels of Drd2 in both brain areas under the application of MAM. The "co-factor genes" did not show high deviations in mRNA expression levels but high alterations of methylation rates under the application of MAM (up to ~20%), which diminished in the further time course, reaching a comparable level like in Sham control animals after adolescence. The pre-adolescent reduction in DRD2 expression might be interpreted as downregulation of the receptor due to hyperdopaminergic signaling from the ventral tegmental area (VTA), eventually even to both investigated brain regions. The notable alterations of methylation rates in the three analyzed co-factor genes might be interpreted as attempt to compensate for the altered dopaminergic neurotransmission.

Trajectory of change in brain complement factors from neonatal to young adult humans

CSMD1 regulates brain complement activity and circuit development

Association of Elevated Levels of Peripheral Complement Components with Cortical Thinning and Impaired Logical Memory in Drug-Naïve Patients with First-Episode Schizophrenia

Association of the Plasma Complement System with Brain Volume Deficits in Bipolar and Major Depressive Disorders

Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice

Schizophrenia risk from complex variation of complement component 4

The schizophrenia risk gene C4 induces pathological synaptic loss by impairing AMPAR trafficking

The Classical Complement Cascade Mediates CNS Synapse Elimination

Decreased Thalamic Expression Of The Homeobox Gene Dlx1 In Psychosis

Cortical gene expression architecture links healthy neurodevelopment to the imaging, transcriptomics, and genetics of autism and schizophrenia

Complement in Neurologic Disease

The Importance of Complement-Mediated Immune Signaling in Alzheimer's Disease Pathogenesis

Lower complement C1q levels in first-episode psychosis and in schizophrenia

Beneficial versus Detrimental Effects of Complement–Microglial Interactions in Alzheimer's Disease

Complement and microglia mediate early synapse loss in Alzheimer mouse models

Serum Complement Proteins Rather Than Inflammatory Factors is Effective in Predicting Psychosis in Individuals at Clinical High Risk

Associations Between Genotype and Peripheral Complement Proteins in First-Episode Psychosis: Evidences from C3 and C4.

C1q and immunoglobulins mediate activity-dependent synapse loss in the adult brain

Soluble terminal complement complex blood levels are elevated in schizophrenia

Alzheimer's disease-associated complement gene variants influence plasma complement protein levels

Methylation pattern and mRNA expression of synapse-relevant genes in the MAM model of schizophrenia in the time-course of adolescence